Abstract:Mitochondria are heterogeneous and highly dynamic organelles, playing critical roles in adenosine triphosphate (ATP) synthesis, metabolic modulation, reactive oxygen species (ROS) generation, and cell differentiation and death. Mitochondrial dysfunction has been recognized as a contributor in many diseases. The kidney is an organ enriched in mitochondria and with high energy demand in the human body. Recent studies have been focusing on how mitochondrial dysfunction contributes to the pathogenesis of different forms of kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD). AKI has been linked to an increased risk of developing CKD. AKI and CKD have a broad clinical syndrome and a substantial impact on morbidity and mortality, encompassing various etiologies and representing important challenges for global public health. Renal mitochondrial disorders are a common feature of diverse forms of AKI and CKD, which result from defects in mitochondrial structure, dynamics, and biogenesis as well as crosstalk of mitochondria with other organelles. Persistent dysregulation of mitochondrial homeostasis in AKI and CKD affects diverse cellular pathways, leading to an increase in renal microvascular loss, oxidative stress, apoptosis, and eventually renal failure. It is important to understand the cellular and molecular events that govern mitochondria functions and pathophysiology in AKI and CKD, which should facilitate the development of novel therapeutic strategies. This review provides an overview of the molecular insights of the mitochondria and the specific pathogenic mechanisms of mitochondrial dysfunction in the progression of AKI, CKD, and AKI to CKD transition. We also discuss the possible beneficial effects of mitochondrial-targeted therapeutic agents for the treatment of mitochondrial dysfunction-mediated AKI and CKD, which may translate into therapeutic options to ameliorate renal injury and delay the progression of these kidney diseases.

The Role of PGC-1α and Mitochondrial Biogenesis in Kidney Diseases

Tubular Mitochondrial Dysfunction, Oxidative Stress, and Progression of Chronic Kidney Disease

PGC1-α in diabetic kidney disease: unraveling renoprotection and molecular mechanisms

PGC-1α in Disease: Recent Renal Insights into a Versatile Metabolic Regulator

Emerging Protective Actions of PGC-1α in Diabetic Nephropathy

Targeting the progression of chronic kidney disease

Activation of Peroxisome Proliferator-Activated Receptor-Γ Coactivator 1α Ameliorates Mitochondrial Dysfunction and Protects Podocytes from Aldosterone-Induced Injury.

Role of mitochondria in reno-cardiac diseases: A study of bioenergetics, biogenesis, and GSH signaling in disease transition

The Role of Mitochondria in Acute Kidney Injury and Chronic Kidney Disease and Its Therapeutic Potential

The role of mitophagy in the development of chronic kidney disease

Mitochondrial Signaling, the Mechanisms of AKI-to-CKD Transition and Potential Treatment Targets

Protective Role of PGC-1α in Diabetic Nephropathy is Associated with the Inhibition of ROS Through Mitochondrial Dynamic Remodeling.

Protective Effects of PGC-1α on the Blood Brain Barrier After Acute Kidney Injury

From physiology to pathology: the role of mitochondria in acute kidney injuries and chronic kidney diseases

Role of PGC-1α in the Mitochondrial NAD+ Pool in Metabolic Diseases

Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α Inhibits Vascular Calcification Through Sirtuin 3-Mediated Reduction of Mitochondrial Oxidative Stress.

PGC-1α Alleviates Mitochondrial Dysfunction Via TFEB-mediated Autophagy in Cisplatin-Induced Acute Kidney Injury

Dysfunction of the PGC-1α-mitochondria Axis Confers Adriamycin-Induced Podocyte Injury.

PGC-1α Overexpression Protects Against Aldosterone-Induced Podocyte Depletion: Role of Mitochondria

Design and optimization strategies for the development of new drugs that treat chronic kidney disease

Molecular Mechanisms of Kidney Injury and Repair